Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The epidermal growth factor receptor (EGFR) gene plays a crucial role in cell growth and is implicated in various cancers.
• Mutations in the tyrosine kinase domain of EGFR have been identified in a subset of lung cancers.
• These mutations predict sensitivity to specific targeted therapies, known as tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To explore the significance of EGFR gene mutations in lung cancer.
• To review the current understanding of targeted therapies for lung cancer based on EGFR status.
• To discuss the ongoing research and controversies surrounding biomarkers for predicting response to EGFR TKIs.

Main Methods:

• Review of existing scientific literature on EGFR mutations and lung cancer.
• Analysis of clinical and translational research findings.
• Discussion of molecular, pathological, and clinical features of EGFR-mutated lung cancers.

Main Results:

• EGFR mutations define a subset of lung cancers responsive to targeted therapy.
• EGFR abnormalities suggest distinct molecular pathways in lung cancer pathogenesis between smokers and never-smokers.
• The optimal biomarker for predicting response to EGFR TKIs remains under investigation.

Conclusions:

• EGFR mutations are a key factor in targeted lung cancer therapy.
• Further research is needed to refine predictive biomarkers for EGFR TKI treatment.
• Understanding EGFR alterations provides insights into lung cancer heterogeneity.